S-8 1 d138938ds8.htm S-8 S-8

As filed with the U.S. Securities and Exchange Commission on March 25, 2021

Registration No. 333-                    

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

NEOLEUKIN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   98-0542593

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

188 East Blaine Street, Suite 450

Seattle, Washington 98102

(866) 245-0312

(Address of principal executive offices) (Zip code)

Neoleukin Therapeutics, Inc. 2014 Equity Incentive Plan

(Full title of the plan)

Jonathan G. Drachman

Chief Executive Officer

Neoleukin Therapeutics, Inc.

360-1616 Eastlake Avenue East

Seattle, Washington 98102

(206) 732-2133

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

 

 

Please send copies of all communications to:

Effie Toshav, Esq.

Robert Freedman, Esq.

Julia Forbess, Esq.

Fenwick & West LLP

555 California Street, 12th Floor

San Francisco, California 94104

(415) 875-2300

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities

to be Registered

 

Amount

to be

Registered (1)

 

Proposed

Maximum

Offering Price

per Share (3)

 

Proposed

Maximum

Aggregate

Offering Price (3)

 

Amount of

Registration Fee

Common Stock, par value $0.000001 per share

  1,687,852 (2)   $11.43   $19,292,149   $2,105

 

 

(1)

Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the plan set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock.

(2)

Represents additional shares of common stock reserved for issuance under the Registrant’s 2014 Equity Incentive Plan, as amended as of January 1, 2021.

(3)

Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $11.43, the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on March 18, 2021.

 

 

 


EXPLANATORY NOTE

REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

This Registration Statement on Form S-8 is being filed by Neoleukin Therapeutics, Inc. (the “Registrant”) for the purpose of registering an additional 1,687,852 shares of the Registrant’s common stock to be issued pursuant to the Registrant’s 2014 Equity Incentive Plan, as amended (the “2014 EIP”). These additional shares of common stock are securities of the same class as other securities for which registration statements on Form S-8 (File Nos. 333-194490, 333-203179, 333-210172, 333-216572, 333-223589, 333-234734 and 333-237124) were filed with the Securities and Exchange Commission (the “Commission”) on March 11, 2014, April 1, 2015, March 14, 2016, March 9, 2017, March 12, 2018, November 15, 2019 and March 12, 2020, respectively. These additional shares of common stock have become reserved for issuance as a result of the operation of the “evergreen” provision in the 2014 EIP, which provides that the total number of shares subject to such plan will be increased on January 1 of each year pursuant to a specified formula through January 1, 2024.

PART II

 

ITEM 3.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

(a) the description of the Registrant’s common stock which is contained in the Registrant’s registration statement on Form 8-A filed on March 3, 2014 (File No. 001-36327) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including any amendment or report filed for the purpose of updating such description;

(b) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, which includes audited financial statements for the Registrant’s latest fiscal year, filed with the Commission on March 25, 2021; and

(c) all other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

ITEM 5.

INTERESTS OF NAMED EXPERTS AND COUNSEL

As of the date of this Registration Statement, attorneys of Fenwick & West LLP beneficially own an aggregate of approximately 3,000 shares of the Registrant’s common stock.


ITEM 8.

EXHIBITS

 

Exhibit
Number

  

Exhibit Description

  

Incorporated by Reference

  

Filed
Herewith

  

Form

  

File No.

  

Exhibit

  

Filing Date

  4.1    Amended and Restated Certificate of Incorporation of the Registrant    8-K    001-36327    3.1    March 12,
2014
  
  4.2    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant    10-Q    001-36327    3.4    November 13,
2019
  
  4.3    Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant    10-Q    001-36327    3.5    November 13,
2019
  
  4.4    Amended and Restated Bylaws of the Registrant    8-K    001-36327    3.1    April 13, 2020   
  4.5    Specimen Common Stock Certificate of the Registrant    10-Q    001-36327    4.1    May 13, 2014   
  5.1    Opinion of Fenwick & West LLP                X
23.1    Consent of Fenwick & West LLP (contained in Exhibit 5.1)                X
23.2    Consent of Deloitte LLP, Independent Registered Public Accounting Firm                X
23.3    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm                X
24.1    Power of Attorney (included on the signature page to this Registration Statement)                X
99.1    2014 Equity Incentive Plan, as amended    8-K    001-36327    10.1    November 14,
2019
  
99.2    Forms of Option Agreement and Option Grant Notice for Registrant’s 2014 Equity Incentive Plan    S-1    333-193615    10.4    January 28,
2014
  


ITEM 9.

UNDERTAKINGS

A. The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.

Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

B. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

C. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Seattle, Washington on this 25th day of March, 2021.

 

NEOLEUKIN THERAPEUTICS, INC.
By:  

/s/ Jonathan G. Drachman, M.D.

  Jonathan G. Drachman, M.D.
  Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jonathan G. Drachman and Robert Ho, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him and in his name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

 

Signature

  

Title

 

Date

/s/ Jonathan G. Drachman, M.D.

Jonathan G. Drachman, M.D.

  

President, Chief Executive Officer and Director

(Principal Executive Officer)

  March 25, 2021

/s/ Robert Ho

Robert Ho

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

  March 25, 2021

/s/ Martin Babler

Martin Babler

  

Director

  March 25, 2021

/s/ M. Cantey Boyd

M. Cantey Boyd

  

Director

  March 25, 2021

/s/ Erin Lavelle

Erin Lavelle

  

Director

  March 25, 2021

/s/ Sarah B. Noonberg, M.D., Ph.D.

Sarah B. Noonberg, M.D., Ph.D.

  

Director

  March 25, 2021

/s/ Todd Simpson

Todd Simpson

  

Director

  March 25, 2021

/s/ Lewis T. “Rusty” Williams, M.D., Ph.D.

Lewis T. “Rusty” Williams, M.D., Ph.D.

  

Director

  March 25, 2021